Central nervous system depressant, analgesic and monoamine oxidase inhibitory properties of substituted piperidines. 1984

B R Pandey, and D K Agrawal, and S S Parmar, and W W Willson, and G G Mayer

Eight 1-(arylaminothiocarbonyl)-4-hydroxy-4-phenyl piperidines were evaluated for their central nervous system depressant, analgesic, and monoamine oxidase inhibitory properties. The central nervous system depressant property of these substituted piperidines was reflected by their ability to potentiate pentobarbital-induced sleep in mice ranging from 18.3 to 58.5 minutes. The analgesic activity possessed by these substituted piperidines, with the exception of one compound, was shown by their ability to provide 16.7 to 50 percent protection against tail pinch response in mice. All substituted piperidines (1 mM) inhibited in vitro activity of rat brain monoamine oxidase with the degree of inhibition ranging from 17.2 to 18.3 percent.

UI MeSH Term Description Entries
D008297 Male Males
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D010146 Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS. Suffering, Physical,Ache,Pain, Burning,Pain, Crushing,Pain, Migratory,Pain, Radiating,Pain, Splitting,Aches,Burning Pain,Burning Pains,Crushing Pain,Crushing Pains,Migratory Pain,Migratory Pains,Pains, Burning,Pains, Crushing,Pains, Migratory,Pains, Radiating,Pains, Splitting,Physical Suffering,Physical Sufferings,Radiating Pain,Radiating Pains,Splitting Pain,Splitting Pains,Sufferings, Physical
D010880 Piperidines A family of hexahydropyridines.
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002492 Central Nervous System Depressants A very loosely defined group of drugs that tend to reduce the activity of the central nervous system. The major groups included here are ethyl alcohol, anesthetics, hypnotics and sedatives, narcotics, and tranquilizing agents (antipsychotics and antianxiety agents). CNS Depressants,Depressants, CNS
D000700 Analgesics Compounds capable of relieving pain without the loss of CONSCIOUSNESS. Analgesic,Anodynes,Antinociceptive Agents,Analgesic Agents,Analgesic Drugs,Agents, Analgesic,Agents, Antinociceptive,Drugs, Analgesic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012890 Sleep A readily reversible suspension of sensorimotor interaction with the environment, usually associated with recumbency and immobility. Sleep Habits,Sleeping Habit,Sleeping Habits,Habit, Sleep,Habit, Sleeping,Habits, Sleep,Habits, Sleeping,Sleep Habit
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

B R Pandey, and D K Agrawal, and S S Parmar, and W W Willson, and G G Mayer
September 1982, Research communications in chemical pathology and pharmacology,
B R Pandey, and D K Agrawal, and S S Parmar, and W W Willson, and G G Mayer
April 2014, Asian Pacific journal of tropical biomedicine,
B R Pandey, and D K Agrawal, and S S Parmar, and W W Willson, and G G Mayer
January 1975, Journal of pharmaceutical sciences,
B R Pandey, and D K Agrawal, and S S Parmar, and W W Willson, and G G Mayer
December 1973, Journal of pharmaceutical sciences,
B R Pandey, and D K Agrawal, and S S Parmar, and W W Willson, and G G Mayer
September 1962, Activitas nervosa superior,
B R Pandey, and D K Agrawal, and S S Parmar, and W W Willson, and G G Mayer
February 1979, Research communications in chemical pathology and pharmacology,
B R Pandey, and D K Agrawal, and S S Parmar, and W W Willson, and G G Mayer
November 2017, International journal of biological macromolecules,
B R Pandey, and D K Agrawal, and S S Parmar, and W W Willson, and G G Mayer
October 1972, Journal of medicinal chemistry,
B R Pandey, and D K Agrawal, and S S Parmar, and W W Willson, and G G Mayer
January 1963, Acta biologica et medica Germanica,
B R Pandey, and D K Agrawal, and S S Parmar, and W W Willson, and G G Mayer
January 1967, Acta histochemica,
Copied contents to your clipboard!